DCT

2:26-cv-11266

Axsome Therap Inc v. Apotex Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Axsome Therapeutics, Inc. v. Apotex Inc., 2:26-cv-11266, D.N.J., 08/31/2026
  • Venue Allegations: Venue is alleged to be proper as Defendant is a foreign corporation that may be sued in any judicial district and has purposefully availed itself of the privileges of conducting business in New Jersey.
  • Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's Symbravoflex® (meloxicam and rizatriptan) tablets constitutes an act of patent infringement under the Hatch-Waxman Act for twenty-one patents.
  • Technical Context: The technology concerns pharmaceutical formulations designed to improve the bioavailability and speed the onset of action of meloxicam, a non-steroidal anti-inflammatory drug (NSAID), for the treatment of pain and migraine.
  • Key Procedural History: The lawsuit was triggered by Defendant Apotex Inc.'s filing of ANDA No. 220803 with the FDA, seeking to market a generic drug prior to the expiration of Plaintiff's patents. In connection with its ANDA, Apotex provided Paragraph IV certifications alleging that the patents-in-suit are invalid and/or will not be infringed by its proposed product. The complaint also notes a related matter between the same parties in the same district, Case No. 25-16038.

Case Timeline

Date Event
2015-02-10 Earliest Priority Date ('399, '400, '484, '225, '471 Patents)
2017-01-08 Priority Date ('657 Patent)
2017-09-09 Priority Date ('078, '079 Patents)
2019-04-11 Priority Date ('683 Patent)
2019-04-23 Issue Date ('399 Patent)
2019-04-23 Issue Date ('400 Patent)
2019-06-04 Issue Date ('484 Patent)
2019-08-06 Issue Date ('225 Patent)
2019-10-29 Issue Date ('471 Patent)
2019-11-18 Priority Date ('256, '257, '258 Patents)
2019-12-02 Priority Date ('176 Patent)
2021-02-10 Priority Date ('383 Patent)
2021-02-17 Priority Date ('488, '489 Patents)
2021-04-28 Priority Date ('413 Patent)
2021-05-05 Priority Date ('752 Patent)
2021-07-21 Priority Date ('5,736 Patent)
2021-07-28 Priority Date ('123 Patent)
2022-03-08 Issue Date ('657 Patent)
2022-05-19 Priority Date ('118 Patent)
2022-09-06 Issue Date ('078 Patent)
2022-09-06 Issue Date ('079 Patent)
2024-04-02 Issue Date ('683 Patent)
2024-06-11 Issue Date ('118 Patent)
2025-11-18 Issue Date ('256 Patent)
2025-11-18 Issue Date ('257 Patent)
2025-11-18 Issue Date ('258 Patent)
2025-12-02 Issue Date ('176 Patent)
2026-02-10 Issue Date ('383 Patent)
2026-02-17 Issue Date ('488 Patent)
2026-02-17 Issue Date ('489 Patent)
2026-04-28 Issue Date ('413 Patent)
2026-05-05 Issue Date ('752 Patent)
2026-07-21 Issue Date ('5,736 Patent)
2026-07-28 Issue Date ('123 Patent)
(pre-2026-08-31) Apotex files ANDA No. 220803
2026-08-31 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,265,399 - "Pharmaceutical Compositions Comprising Meloxicam"

Issued April 23, 2019

The Invention Explained

  • Problem Addressed: The patent identifies that meloxicam, a non-steroidal anti-inflammatory drug (NSAID), has poor aqueous solubility, which can reduce its bioavailability and slow the onset of pain relief after oral administration '399 Patent, col. 2:43-46
  • The Patented Solution: To solve this, the invention proposes a composition that combines meloxicam with a cyclodextrin and a carbonate or bicarbonate '399 Patent, abstract The cyclodextrin forms an inclusion complex with meloxicam, increasing its solubility, while the carbonate/bicarbonate acts as a buffering agent to increase the pH of the stomach, further enhancing the speed at which meloxicam is absorbed into the bloodstream '399 Patent, col. 2:49-56 '399 Patent, col. 3:1-5
  • Technical Importance: This formulation approach is intended to provide a more rapid onset of therapeutic effect for meloxicam, which is particularly beneficial for treating acute conditions such as pain or migraine where fast relief is desired '399 Patent, col. 9:43-47

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶42
  • Claim 1 Elements:
    • A method of improving the pharmacokinetics of meloxicam in a human subject,
    • comprising orally administering a solid dosage form comprising meloxicam, a cyclodextrin, and a bicarbonate or a carbonate to the human subject,
    • wherein the oral dosage form is a tablet.
  • The complaint reserves the right to assert additional claims Compl. ¶42

U.S. Patent No. 10,265,400 - "Pharmaceutical Compositions Comprising Meloxicam"

Issued April 23, 2019

The Invention Explained

  • Problem Addressed: Similar to the '399 Patent, this patent addresses the slow onset of action for meloxicam due to its poor solubility '400 Patent, col. 2:43-46
  • The Patented Solution: The patent describes combining meloxicam and rizatriptan in a dosage form that achieves specific pharmacokinetic (PK) profiles, suggesting improved absorption '400 Patent, col. 1:21-25 '400 Patent, abstract The specification, shared with the '399 patent, discloses using cyclodextrin and a buffering agent to achieve this rapid absorption '400 Patent, col. 2:49-3:5
  • Technical Importance: By achieving a rapid peak plasma concentration (Tmax) and a specific total drug exposure (AUC), the formulation aims to provide fast and effective treatment for migraine, a condition where rapid relief is a primary clinical goal '400 Patent, summary

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶51
  • Claim 1 Elements:
    • A method of treating migraine,
    • comprising orally administering a solid dosage form comprising a combination of meloxicam and rizatriptan to a human being,
    • wherein the combination provides a Tmax of meloxicam of 110 minutes or less,
    • and an AUC0-24 of meloxicam of about 30 µg·hr/mL to about 50 µg·hr/mL.
  • The complaint reserves the right to assert additional claims Compl. ¶51

Multi-Patent Capsule: U.S. Patent No. 10,307,484

  • Patent Identification: U.S. Patent No. 10,307,484, "Pharmaceutical Compositions Comprising Meloxicam," issued June 4, 2019 Compl. ¶7
  • Technology Synopsis: The patent describes pharmaceutical compositions of meloxicam combined with a cyclodextrin and a carbonate/bicarbonate to enhance bioavailability and speed of action '484 Patent, abstract It claims methods of treatment that result in specific pharmacokinetic outcomes, such as a rapid Tmax.
  • Asserted Claims: At least Claim 1 Compl. ¶60
  • Accused Features: Apotex's proposed generic meloxicam and rizatriptan tablets Compl. ¶¶59-62

Multi-Patent Capsule: U.S. Patent No. 10,369,225

  • Patent Identification: U.S. Patent No. 10,369,225, "Pharmaceutical Compositions Comprising Meloxicam," issued August 6, 2019 Compl. ¶8
  • Technology Synopsis: The patent covers methods of treating pain or migraine by administering a composition of meloxicam, a cyclodextrin, and a bicarbonate/carbonate '225 Patent, abstract The claims focus on achieving specific pharmacokinetic parameters, including Tmax and bioavailability improvements, compared to a reference drug.
  • Asserted Claims: At least Claim 1 Compl. ¶69
  • Accused Features: Apotex's proposed generic meloxicam and rizatriptan tablets Compl. ¶¶68-71

The complaint asserts nineteen additional patents. These patents are part of the same family, share overlapping specifications, and claim various formulations and methods of use related to compositions of meloxicam, cyclodextrin, and buffering agents, sometimes in combination with rizatriptan. For each, the complaint alleges infringement of at least claim 1 based on Apotex's ANDA filing. The additional patents are: '471, '657, '078, '079, '683, '118, '256, '257, '258, '176, '383, '488, '489, '413, '752, '5,736, and '123 Compl. ¶¶9-25

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Apotex's Proposed Product," a generic version of Axsome's Symbravoflex® (meloxicam and rizatriptan) tablets, for which Apotex has filed Abbreviated New Drug Application (ANDA) No. 220803 with the U.S. Food and Drug Administration (FDA) Compl. ¶1 Compl. ¶37

Functionality and Market Context

The complaint alleges that Apotex seeks approval to manufacture and sell its product for the acute treatment of migraine with or without aura in adults, the same indication as Symbravoflex® Compl. ¶1 Compl. ¶26 As an ANDA product, Apotex's generic is intended to be a bioequivalent, lower-cost alternative to the branded drug. The act of infringement alleged is the filing of the ANDA itself, which seeks approval for a use claimed in the patents-in-suit prior to their expiration Compl. ¶37

IV. Analysis of Infringement Allegations

The complaint does not provide detailed, element-by-element infringement allegations or claim charts. This is typical in ANDA litigation, where the statutory act of infringement is the filing of the ANDA, and the infringement analysis is based on the premise that the generic product, if approved, will be used in accordance with its proposed label, thereby practicing the patented methods.

  • Infringement Allegations for '399 Patent and '400 Patent:
    The complaint alleges that Apotex's submission of its ANDA constitutes an act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶42 Compl. ¶51 The central theory is that the proposed label for Apotex's generic product will instruct medical professionals and patients to administer the drug in a way that practices the methods claimed in the patents-in-suit. For example, administering the accused tablet to a human to treat migraine would allegedly infringe the method claims of the asserted patents, such as claim 1 of the '399 Patent and claim 1 of the '400 Patent Compl. ¶44 Compl. ¶53 Because the complaint does not provide specific factual allegations mapping the elements of the accused product to the claim limitations, a detailed claim chart summary cannot be constructed.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

  • The Term: "about" (as in "about 30 µg·hr/mL to about 50 µg·hr/mL" in claim 1 of the '400 Patent)

    • Context and Importance: This term appears in numerous claims across the patent family that define the invention using specific pharmacokinetic parameters (e.g., AUC) or component dosages. The scope of "about" will be critical in determining whether the bioequivalence data for Apotex's product falls within the claimed ranges. A narrow definition could allow Apotex to design around the claims, while a broad definition would make infringement more likely.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patents state that "about" is meant to encompass variations, suggesting the numerical values are not absolute and rigid '400 Patent, col. 18:1-7 This supports a flexible range.
      • Evidence for a Narrower Interpretation: The patents provide an explicit, tiered definition: "'about' . . . is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value" '400 Patent, col. 18:1-7 A defendant may argue that the patentee has defined its own, specific lexicography for "about," potentially limiting its scope more than the default "reasonable approximation" standard.

  • The Term: "cyclodextrin" (as in claim 1 of the '399 Patent)

    • Context and Importance: This is a key excipient in the claimed formulation. While the claim uses the general term, the specification lists numerous specific types of cyclodextrins, including β-cyclodextrin, hydroxypropyl-β-cyclodextrin (HPBCD), and sulfobutyl ether β-cyclodextrin (SBEβCD) '399 Patent, col. 4:40-5:36 The dispute may turn on whether the specific cyclodextrin used in Apotex's formulation is covered by the claim, and whether the term should be limited to the specific examples disclosed.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The use of the general term "a cyclodextrin" in the claim itself suggests the invention is not limited to any single type. The specification lists many examples as embodiments, not limitations '399 Patent, col. 4:40-5:36
      • Evidence for a Narrower Interpretation: The specification provides detailed examples and data using specific cyclodextrins like SBEβCD '399 Patent, Example 3 A defendant might argue that these specific embodiments define the true scope of the invention and that other types of cyclodextrins would not achieve the same results.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement for all asserted patents. The basis for this allegation is that Apotex's future marketing, sale, and labeling of its proposed generic product will actively encourage and instruct physicians and patients to use the product in a manner that directly infringes Axsome's method claims Compl. ¶45 Compl. ¶54 The complaint also alleges contributory infringement, stating that Apotex's product is designed for an infringing use and lacks a substantial non-infringing use Compl. ¶46 Compl. ¶55
  • Willful Infringement: The complaint does not use the term "willful infringement." However, for each patent, it alleges that the case is "exceptional" and seeks an award of reasonable attorneys' fees pursuant to 35 U.S.C. § 285 Compl. ¶49 Compl. ¶57 The basis for this is Apotex's alleged knowledge of the patents-in-suit, evidenced by its filing of Paragraph IV certifications Compl. ¶38

VII. Analyst's Conclusion: Key Questions for the Case

  1. Pharmacokinetic (PK) Profile Infringement: A central question for many asserted claims will be whether Apotex's proposed generic product meets the specific PK parameters (e.g., Tmax, AUC) recited in the claims. This will likely involve a technical battle over the parties' respective bioequivalence studies and the statistical methods used to interpret them.

  2. Scope of "About": The construction of the term "about" will be a pivotal issue. The patents provide an unusually specific, tiered definition for the term. The court's decision on whether this definition strictly limits the claimed numerical ranges, or still allows for some flexibility, could determine the outcome of infringement for numerous claims.

  3. Validity in Light of Formulation Art: Given that Apotex filed a Paragraph IV certification, a primary defense will be patent invalidity. The key question will be whether the combination of known elements-meloxicam, a cyclodextrin, and a buffering agent-to achieve faster absorption was obvious to a person of ordinary skill in the art at the time of the invention. The court will need to analyze whether the claimed PK results were unexpected and synergistic, or merely the predictable outcome of combining known ingredients for their known purposes.